Skip to main
HOTH

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics is well-positioned for growth due to its diverse pipeline of novel therapies targeting unmet medical needs in cancer, skin toxicities, Alzheimer's, and weight management. The company has shown promising results in early clinical trials, with no serious adverse events and sustained response in its topical formulation for EGFR therapy-associated skin toxicities. With continued development and potential partnerships, Hoth has the potential to become a leader in the biopharmaceutical industry.

Bears say

Hoth Therapeutics is deploying AI infrastructure to support the development of HT-KIT, an orphan-designated therapy targeting rare KIT-driven cancers. The program has received Orphan Drug Designation and has completed GLP-validated bioanalytical methods to support IND submission. With potential approvals in multiple EU countries and encouraging data in EGFR inhibitor-associated rash and a VA-led GDNF study, as well as progress on joint venture programs, Hoth could see incremental value in its dual-track strategy.

Hoth Therapeutics (HOTH) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.